The present disclosure relates to skin closure systems and devices comprising elastic flat flexible tape elongated along a main axis and having a lower side and an opposing upper side, said tape having a pressure sensitive adhesive on at least a portion of the lower side, said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the main axis. Skin closure device is applied over a surgical incision and secured by polymerizable adhesive.
A number of devices and methods exist for closing skin or tissue having a surgical opening, cut, wound, or dissection, whereby skin or tissue parts separated by the cut are approximated or brought into close proximity forming as narrow gap as possible in the area of the surgical dissection or cut, and then covered by an adhesively attached tape which holds the skin or tissue in closed apposed arrangement until wound healing whereby the tape is removed.
Commercially available DERMABOND® PRINEO® Skin Closure System comprises a mesh having a pressure sensitive adhesive and a polymerization initiator disposed on the mesh. The mesh is applied onto the skin over a wound, and a polymerizable cyanoacrylate based adhesive is then applied on the mesh and bonds the mesh to the skin. However, skin closure systems, such as DERMABOND® PRINEO® Skin Closure System, may benefit from more stretching for flexibility/joint articulation if applied over a joint, such as knee, elbow, or similar, while holding the dissection applied lengthwise or longitudinally along the joint.
A number of attempts to address this issue are known, including commercial products: such as TopClosure® 3S System—Skin Stretching and Secure Wound Closure System; Steri-Strip™ by 3M™; Zip®16 Surgical Skin Closure by Zipline Medical. These known systems are complex and either lack flexibility or lack secure and lasting bonding and coverage which extends for the time needed for full healing, such as 1-2 weeks.
PCT publication No. WO2008/082444 titled “Articles and Methods for Tissue Repair” discloses a method of medically treating a tissue comprising: directing a transfer device to a tissue surface, the transfer device having associated therewith a patterned array of an adhesive; transferring at least a portion of the patterned array of adhesive from the transfer device to the tissue surface by contact adhesion; moving the transfer device away from the tissue surface; positioning an article to be adhered adjacent at least a portion of the adhesive; and adhering the article to the tissue surface using the adhesive.
U.S. Pat. No. 8,353,966 entitled “Scaffold for Bone and Tissue Repair in Mammals” discloses a tissue scaffold for repair and regeneration of bone hard tissue or muscle, skin, or organ soft tissue, the scaffold comprising: a rigid scaffold body having a scaffold central axis, a scaffold transverse dimension, and a scaffold lengthwise dimension which is greater than the scaffold transverse dimension, the scaffold body having a compressive strength between about 20 and about 250 MPa and comprising: biocompatible inorganic glass fibers each having a fiber transverse dimension and a fiber lengthwise dimension which is at least about 10 times the fiber transverse dimension; and an interconnected porosity constituting between about 10 vol. % and about 35 vol. % of the scaffold body; wherein each of the fibers has a diameter between about 20 and about 5000 microns; wherein at least about 75 vol. % of the fibers are longitudinally co-aligned and lie generally lengthwise of the scaffold central axis, are generally free of helical orientation about the scaffold central axis, and are arranged to define open channels within the scaffold which allow fluid flow into and lengthwise within the scaffold; and wherein the fibers are self-bonded together in that adjacent longitudinally aligned fibers are fused together.
U.S. Pat. No. 6,652,559 entitled “Wound Closure System” discloses a wound closure system for closing a wound on a patient, comprising: an elongated flexible backing strip having opposite ends, first and second surfaces facing away from one another and a length and width sufficient to secure facing edges of the wound in close juxtaposition to one another, said backing strip comprising a first portion disposed between said ends and adapted to overlie the facing edges of said wound, and second and third portions disposed on either side of said first portion and each provided with a predetermined number of spaced-apart perforations extending through said backing strip from said first surface to said second surface, said first portion being free of any aperture extending through said backing strip from said first surface to said second surface; a first pressure-sensitive adhesive coated on at least part of the first surface of said backing strip including said second and third portions thereof, to adhere at least said second and third portions of said backing strip to the patient with the facing edges of said wound in said close juxtaposition; a first protective member removably attached to said backing strip and covering said pressure-sensitive adhesive; and a flowable, moisture-curable surgical adhesive for application into said perforations to strengthen the adhesion of said second and third portions of said backing strip to the patient; whereby after (a) removal of said protective member to expose said pressure-sensitive adhesive, (b) application of said backing strip with the exposed pressure-sensitive adhesive onto said patient to secure the facing edges of said wound in said close juxtaposition, and (c) application of said surgical adhesive into said apertures, said surgical adhesive flows through said perforations and upon curing forms discrete bonding sites cooperating with said backing strip to maintain the facing edges of said wound in said close juxtaposition without the cured adhesive adversely affecting the flexibility of said backing strip, wherein a second protective member having a second pressure-sensitive adhesive coated on one side thereof is removably attached to said backing strip and covers said second surface, said strip being disposed between said first and second protective members, and wherein said second protective member is provided with a corresponding number of perforations registering with the perforations defined in said second and third portions of said backing strip, and being in flow communication therewith.
U.S. Pat. No. 6,559,350 entitled “MOISTURE-CURABLE ADHESIVE SUTURE STRIP” discloses a moisture-curable adhesive suture strip for closing a wound on a patient, comprising: an elongated, flexible air-permeable backing member formed of a chemically inert material, and having opposite ends, first and second surfaces facing away from one another and a length and width adapted to secure facing edges of the wound in close juxtaposition to one another, said backing member comprising a first portion disposed between said ends and adapted to overlie the facing edges of said wound, and second and third portions disposed on either side of said first portion; a moisture-curable surgical adhesive on at least part of the first surface of said backing member including said second and third portions thereof, in spaced-apart discrete areas of said first surface; a pressure-sensitive adhesive on the first surface of said backing member between said discrete areas for adhering at least said second and third portions of said backing member to the patient with the facing edges of said wound in said close juxtaposition; and a first removable protective member formed of a chemically inert material releasably secured to said backing member and covering said surgical adhesive and said pressure-sensitive adhesive; whereby after removal of said protective member to expose said surgical adhesive and said pressure sensitive adhesive, and application of said backing member with the exposed surgical adhesive pressure sensitive adhesive onto said patient to secure the facing edges of said wound in said close juxtaposition, said surgical adhesive upon curing forms discrete bonding sites strengthening the adhesion of at least said second and third portions of said backing member to the patient and cooperating with said backing member to maintain the facing edges of said wound in said close juxtaposition without the cured adhesive adversely affecting the flexibility of said backing member.
U.S. Patent Application Publication No. 2013/0012988 entitled “Wound Closure Material” discloses wound closure material with a core of biodegradable material, wherein at least one side of the core of biodegradable material is provided with a multitude of discrete spots of an adhesive and the core of biodegradable material comprises an open cell structure.
U.S. Pat. No. 8,642,831 entitled “Device for Promotion of Hemostasis and/or Wound Healing” discloses a hemostatic matrix material comprising a surface and a plurality of open and interconnected cells, said matrix material comprising gelatine or collagen, wherein the surface of said matrix comprises at least one pharmaceutical composition printed onto said surface in individual and discrete locations, wherein said pharmaceutical composition comprises one or more hemostatic agents.
U.S. Patent Application publication No. 2014/0155916 entitled “Multi-layer Porous Film Material” discloses a surgical implant, comprising: a first porous film layer including a plurality of pores; and a second porous film layer including a plurality of pores, the first and second porous film layers being in a stacked configuration and interconnected to one another at a plurality of attachment points to define at least one void between the first and second porous film layers.
U.S. Patent Application publication No. 2008/0109034 entitled “Controlled Adhesive Locations Facilitating Tissue Remodeling” discloses a surgical implant for adhering two portions of tissue together comprising; a) an implantable matrix having at least one layer and a plurality of openings formed within the at least one layer for tissue growth therethrough; and b) a polymer adhesive about the implantable matrix for adhering the two portions of tissue together, the adhesive polymerizing to adhere the tissue together when the two portions of tissue are brought together.
U.S. Patent Application publication No. 2006/0141012 entitled “Tissue Scaffold” discloses a tissue scaffold comprising: a first film including a plurality of cell openings; and a second film adjacent the first film and including a plurality of cell openings larger than the cell openings of the first film; wherein the cell openings of the first film interconnect with the cell openings of the second film to define pathways extending from the first film to the second film.
U.S. Patent Application publication No. 2013/0204077 entitled “Surgical Scaffolds” discloses a surgical scaffold for soft tissue repair, said surgical scaffold comprising a sheet of non-filamentous polymeric material, at least a portion of the sheet surface comprising a plurality of through-holes.
Leukosan® SkinLink by BSN Medical and distributed by Smith and Nephew Pty Ltd, has an apertured band-aid like structure.
Synthetic tissue adhesive TissuGlu® Surgical Adhesive by Cohera Medical, Inc. is based on a polyurethane prepolymer and is applied in a spot-like discrete application of the adhesive during abdominoplasty, using a multi-point dispenser.
Very flexible and elastic tapes will allow for joint flexibility, but will not hold the skin areas in apposed arrangement due to the same elasticity, potentially resulting in wound dehiscence or surgical complication in which a wound ruptures along a surgical incision. Other known systems fail to fully cover the wound resulting in potential for ingress of contaminants and infection causing microorganisms. Other known systems are overly rigid preventing articulation or bending of the joint.
There continues to be a need for improved devices, systems, and methods for holding skin areas around the dissection in apposed arrangement while still providing for flexibility in longitudinal direction enabling bending of the underlying joints.
In one embodiment, a device for skin closure comprises an elastic flat flexible tape elongated along a main axis and having a lower side and an opposing upper side, said tape having a pressure sensitive adhesive on at least a portion of the lower side, said tape having a plurality of openings arranged side-by-side with spaces between said openings oriented across the main axis.
According to another embodiment, there is provided a method of skin closure, comprising the steps of disposing the device onto skin having a surgical incision with the main axis approximately aligned with the surgical incision; apposing and approximating edges of the incision to each other; using the pressure sensitive adhesive to fixate the device on skin; applying a polymerizable adhesive onto the upper side into the openings; Allowing the polymerizable adhesive to polymerize and bond to skin and to the device; rendering the device substantially not stretchable in the directions perpendicular to the main axis but stretchable along the main axis providing for flexibility and enabling bending of underlying joints; providing coverage of the incision and keeping the incision closed.
Referring now to
Referring now to
Mesh 40 alternatively can be a porous nonwoven, felt, porous woven fabric, textile, foam, or similar. Mesh 40 can also be an extruded film porated during or after extrusion or formed directly with apertures.
Tape 20 is made of a polymeric flexible and elastic material. Elastic property is defined by stretchability at least in the lengthwise direction, with stretchability from 1% to 50% of length when exposed to 1 N of force, more preferably 3%-25% of the initial or unstressed length. The ‘elastic’ property is a function of the material from which the mesh is constructed and/or the nature of the mesh construction itself. Mesh 40 is made of flexible material, which can optionally also be elastic. Mesh 40 can be polymeric, metal, ceramic, natural fiber, etc., with preferable material being polymeric. Lower side 23 has optionally a pressure sensitive adhesive (PSA) disposed thereon, which can cover the whole lower side 23, or only a portion of lower side 23 in any pattern. In one embodiment, PSA is applied in equally spaced stripes across whole lower side 23. In another embodiment, PSA is applied only on the areas free of openings 30 on lower side 23. In another embodiment, PSA is applied only on the areas where openings 30 are present on lower side 23 and optionally above and below openings 30. In yet another embodiment, PSA is applied uniformly everywhere on lower side 23.
In use and referring to
The application of adhesive results in device 10 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, device 10 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints, while also providing coverage of the wound or incision. Advantageously, wound dehiscence or surgical complication in which a wound ruptures along a surgical incision is therefore prevented, while also fully covering the wound and enabling articulation or bending of the joint.
Referring now to
According to an embodiment (not shown), there is provided a kit, comprising device 10, a container containing a polymerizable or cross-linkable liquid adhesive, and a dispenser adapted to dispense adhesive. In one embodiment, dispenser has a tip for expressing the polymerizable adhesive, wherein the tip has a width equal to a width of openings 30.
Referring now to
No Mesh
Referring now to
In use and referring to
Mask
Referring now to
In operation, assembled device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto upper side 22, onto the whole upper side 22 surface or more preferably only onto/into openings 30 on upper side 22. Mask 20a is then removed and discarded. All of the excess adhesive is removed on mask 20a. The polymerizable adhesive reacts with the initiator or accelerator of polymerization if disposed on the mesh 40, if coated on the mesh 40, and/or if impregnated into the mesh 40 resulting in polymerization and bonding of the adhesive to the skin or tissue and to mesh 40 in the areas of mesh 40 corresponding to openings 30. The application of adhesive results in mesh 40 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, mesh 40 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints.
Referring now to
In operation, assembled Skin Closure System device with device 10 with mask 20a disposed on upper side 22 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive is then applied onto mask 20a surface or more preferably only onto/into openings 30 and 30a. Mask 20a is then removed and discarded. All of the excess adhesive is removed on mask 20a. The polymerizable adhesive reacts with the initiator or accelerator of polymerization if disposed on the mesh 40, if coated on the mesh 40, and/or if impregnated into the mesh 40 resulting in polymerization and bonding of the adhesive to the skin or tissue and to mesh 40 in the areas of mesh 40 corresponding to openings 30. The application of adhesive results in mesh 40 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in apposed arrangement. Due to presence of the adhesive, mesh 40 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints.
Separate Openings
Referring now to
In use, device 10 is disposed on tissue or skin having a wound with axis 21 approximately aligned with the surgical incision or wound, with the edges of the incision apposed and approximated to each other. A polymerizable adhesive 50 is then applied onto upper side 22, or more preferably only onto/into openings 30b on upper side 22 and onto axial spacer areas 36 formed between openings 30b opposing each other across axis 21, as shown in
The application of adhesive results in device 10 being bonded to the skin and covering the wound or incision while holding skin areas around the dissection in an apposed arrangement and thereby forming a composite of the device with the polymerized adhesive. Due to presence of the adhesive, device 10 is substantially not stretchable in the directions perpendicular to axis 21, keeping the wound or incision closed and skin areas around the dissection in apposed arrangement. At the same time device 10 is stretchable along the main axis providing for flexibility in longitudinal direction enabling bending of the underlying joints, while also providing coverage of the wound or incision. Advantageously, in the embodiments of
Variable Width
Referring now to
Referring now to
Slits
Referring now to
Shapes
In one embodiment, the width W of the device varies along the axis 21. In one embodiment, width W is more narrow in the central region M than at the ends. In another embodiment, width W is wider in the central region M than at the ends.
Referring now to
Referring now to
Referring now to
In one embodiment, there are narrow cuts (not shown) in spacer areas 35 separating openings 30, the cuts comprising narrow slits in tape 20 oriented perpendicular to axis 21 and having length not more than 80% of width W, such as 25, 50%. The cuts can be only between some openings 30 or between all openings 30.
Sizes
Tape 20 can be of any elongated shape to cover an articulating joint, such as elliptical, rectangular, and similar. Tape 20 can have ratio of length to width of about 1:2 to about 1:20, such as 1:5. The length of tape 20 is from about 10 cm to about 50 cm, such as 25 cm. The width of tape 20 is from 2 cm to 10 cm, such 3 cm, 5 cm.
Openings 30 can be rectangular, elliptical, circular, etc., and occupy from 30% to 80% of tape 20 area. Width W′ of openings 30 is from 2 mm to 12 mm, more preferable 3 mm to 10 mm. The longitudinal dimension or length L′ of the openings across the width of the tape W is configured so that openings occupy at least 60% of the tape width W, preferably 60 to 100%, more preferably 70-90% of W. Width W′ of openings 30 is configured to be at least 5% of L′, preferably 5%-100% of L′, more preferably at 20-30% of L′.
Porosity of mesh 40 or tape 20 porated areas in openings 30 is defined by size of pores or holes being from about 0.01 mm2 to about 4 mm2, more preferably 0.1 mm2 to 1 mm2. Percent of open area in mesh 40, or ratio of area of holes to area of material surrounding holes within openings 30 is from about 95%-about 20%, more preferably 90%-40% constituting open area.
PSA
Optional pressure sensitive adhesive bands or stripes are disposed over lower surface 23, (such as shown in
Initiator
In a preferred embodiment, initiators and/or accelerators or rate modifiers of adhesive polymerization or cross-linking can be releasably disposed on mesh 40 or releasably incorporated into mesh 40. For example, one or more chemical substances may be dispersed in or on mesh 40 such as being chemically bound, physically bound, coated, absorbed, or adsorbed to it.
For example, a polymerization initiator or accelerator or rate modifier may be loaded in or on mesh 40 so that the initiator or rate modifier provides the desired initiation or rate modification effect to a subsequently applied polymerizable adhesive composition. The polymerization initiator or rate modifier may be immobilized in or on mesh 40, so that the initiator or rate modifier does not become detached from mesh 40 and its residues are dispersed in the resultant polymeric material. Alternatively, for example, the polymerization initiator or rate modifier may be initially attached to mesh 40, but only in such a manner that it becomes mobilized or solubilized by a subsequently applied polymerizable adhesive composition and dispersed in the resultant polymeric material.
If desired, a combination of chemical substances may also be provided in or on mesh 40, to provide multiple effects. For example, a first chemical species (such as a polymerization initiator or rate modifier) may be immobilized in or on mesh 40, while a second, different chemical species (such as a bioactive material) may be detachably attached to mesh 40. Other combinations of chemical species and resultant effects are also envisioned.
When present in or on mesh 40, the chemical substances (i.e., polymerization initiator, rate modifier, and/or bioactive materials, or other additives), may be incorporated in or on mesh 40 in any suitable manner. For example, the chemical substance may be added to mesh 40 by contacting mesh 40 with a solution, mixture, or the like including the chemical substances. The chemical substance may be added to mesh 40, for example, by dipping, spraying, roll coating, gravure coating, brushing, vapor deposition, or the like. Alternatively, the chemical substance may be incorporated into or onto mesh 40 during manufacture of mesh 40, such as during molding.
The polymerization initiator or rate modifier loaded in or on mesh 40 may provide a number of advantages for example, so as to provide faster polymerization time. The concentration of polymerization initiator or rate modifier may be increased to provide even faster polymerization time.
Because the polymerization initiator or rate modifier is loaded directly in or on mesh 40, it is not necessary to mix the polymerizable adhesive composition with a polymerization initiator or rate modifier prior to application. This may allow a longer working time, where the polymerizable monomer composition may be more precisely and carefully applied over a longer period of time.
Such suitable initiators are known in the art and are described, for example, in U.S. Pat. Nos. 5,928,611 and 6,620,846, both incorporated herein by reference in their entireties, and U.S. Patent Application No. 2002/0037310, also incorporated herein by reference in its entirety. Quaternary ammonium chloride and bromide salts useful as polymerization initiators are particularly suitable. By way of example, quaternary ammonium salts such as domiphen bromide, butyrylcholine chloride, benzalkonium bromide, acetyl choline chloride, among others, may be used.
Benzalkonium or benzyltrialkyl ammonium halides such as benzyltrialkyl ammonium chloride may be used. When used, the benzalkonium halide may be benzalkonium halide in its unpurified state, which comprises a mixture of varying chain-length compounds, or it can be any suitable purified compound including those having a chain length of from about 12 to about 18 carbon atoms, including but not limited to C12, C13, C14, C15, C16, C17, and C18 compounds. By way of example, the initiator may be a quaternary ammonium chloride salt such as benzyltrialkyl ammonium chloride (BTAC).
Other initiators or accelerators may also be selected by one of ordinary skill in the art without undue experimentation. Such suitable initiators or accelerators may include, but are not limited to, detergent compositions; surfactants: e.g., nonionic surfactants such as polysorbate 20 (e.g., Tween 20™ from ICI Americas), polysorbate 80 (e.g., Tween 80™ from ICI Americas) and poloxamers, cationic surfactants such as tetrabutylammonium bromide, anionic surfactants such as sodium tetradecyl sulfate, and amphoteric or zwitterionic surfactants such as dodecyldimethyl(3-sulfopropyl)ammonium hydroxide, inner salt; amines, imines and amides, such as imidazole, arginine and povidine; phosphines, phosphites and phosphonium salts, such as triphenylphosphine and triethyl phosphite; alcohols such as ethylene glycol, methyl gallate; tannins; inorganic bases and salts, such as sodium bisulfate, calcium sulfate and sodium silicate; sulfur compounds such as thiourea and polysulfides; polymeric cyclic ethers such as monensin, nonactin, crown ethers, calixarenes and polymeric-epoxides; cyclic and acyclic carbonates, such as diethyl carbonate; phase transfer catalysts such as Aliquat 336; organometallics such as cobalt naphthenate and manganese acetylacetonate; and radical initiators or accelerators and radicals, such as di-t-butyl peroxide and azobisisobutyronitrile.
Mixtures of two or more, such as three, four, or more, initiators or accelerators may be used. A combination of multiple initiators or accelerators may be beneficial, for example, to tailor the initiator of the polymerizable monomer species. For example, where a blend of monomers is used, a blend of initiators may provide superior results to a single initiator. For example, the blend of initiators can provide one initiator that preferentially initiates one monomer, and a second initiator that preferentially initiates the other monomer, or can provide initiation rates to help ensure that both monomer species are initiated at equivalent, or desired non-equivalent, rates. In this manner, a blend of initiators can help minimize the amount of initiator necessary. Furthermore, a blend of initiators may enhance the polymerization reaction kinetics.
Adhesive
In one embodiment, liquid or semi-liquid adhesive 50 is polymerized or is cross-linking polymerized or is cross-linking after coming in contact with initiators and/or accelerators of adhesive polymerization and/or cross-linking.
Such initiators and/or accelerators can be coated or disposed non-releasably, i.e. immobilized in or on the mesh 40 while retaining activity to initiate or accelerate polymerization and/or cross-linking. In one embodiment, initiators and/or accelerators are disposed releasably, i.e. they can be at least partially released into and mix with flowing adhesive 50.
In a preferred embodiment, adhesive 50 is polymerized or is cross-linking after coming in contact with initiators and/or accelerators releasably disposed in or on the mesh 40. Rapid polymerization and/or crosslinking of adhesive 50 results in bonding of device 10 to tissue.
Adhesive 50 can be any type of biocompatible and rapidly cross-linkable and/or polymerizable compound or mixture of compounds. Rapidly cross-linkable and/or polymerizable means that after initiators or accelerators are added, or after the adhesive is formed from two or more components, it is capable of curing, i.e. cross-linking and/or polymerizing within 0.2 min to about 20 min, more preferably within 0.5 min to 10 min, such as 1, 2, 3, 5 min.
In one embodiment, adhesive 50 is formed prior to application onto mesh 40, for instance by mixing two components contained in separate barrels or a two-barrel syringe, by passing these two components through a mixing tip. In this embodiment, there is no crosslinking initiator or accelerator disposed inside of mesh 40. In one embodiment, adhesive 50 is formed by mixing fibrinogen and thrombin together.
In one embodiment, adhesive 50 comprises fibrinogen, and crosslinking initiator or accelerator disposed inside of mesh 40 comprises thrombin.
In a preferred embodiment, the polymerizable adhesive composition may comprise a polymerizable monomeric adhesive. In embodiments, the polymerizable adhesive composition comprises a polymerizable 1,1-disubstituted ethylene monomer formulation. In embodiments, the polymerizable adhesive composition comprises a cyanoacrylate formulation. In embodiments, synthetic polymerizable adhesive materials such as polyurethane, polyethylene glycol, acrylates, glutaraldehyde and biologically based adhesives may be used.
Suitable .alpha.-cyanoacrylate monomers which may be used, alone or in combination, include alkyl .alpha.-cyanoacrylates such as 2-octyl cyanoacrylate; dodecyl cyanoacrylate; 2-ethylhexyl cyanoacrylate; butyl cyanoacrylate such as n-butyl cyanoacrylate; ethyl cyanoacrylate; methyl cyanoacrylate or other .alpha.-cyanoacrylate monomers such as methoxyethyl cyanoacrylate; 2-ethoxyethyl cyanoacrylate; 3-methoxybutyl cyanoacrylate; 2-butoxyethyl cyanoacrylate; 2-isopropoxyethyl cyanoacrylate; and 1-methoxy-2-propyl cyanoacrylate. In embodiments, the monomers are ethyl, n-butyl, or 2-octyl .alpha.-cyanoacrylate. Other cyanoacrylate monomers which may be used include alkyl ester cyanoacrylates, such as those prepared by the Knoevenagel reaction of an alkyl cyanoacetate, or an alkyl ester cyanoacetate, with paraformaldehyde, subsequent thermal cracking of the resultant oligomer and distillation.
Many other adhesive formulations can be used and are known to a skilled artisan. For example, mixtures containing PEG succinimidyl glutarate can be used as a flowable adhesive.
It should be understood that the foregoing disclosure and description of the embodiments of the present invention are illustrative and explanatory thereof and various changes in the size, shape and materials as well as in the description of the preferred embodiment may be made without departing from the spirit of the invention.
Number | Name | Date | Kind |
---|---|---|---|
167162 | French | Aug 1875 | A |
1656199 | Ensley | Jan 1928 | A |
2399545 | Davis | Apr 1946 | A |
2508855 | Brown | May 1950 | A |
2721858 | Joyner et al. | Oct 1955 | A |
2722220 | Mestrand | Nov 1955 | A |
2807262 | Lew | Sep 1957 | A |
2905174 | Smith | May 1959 | A |
3085572 | Blackford | Apr 1963 | A |
3254111 | Hawkins et al. | May 1966 | A |
3402716 | Baxter | Sep 1968 | A |
3520300 | Flower, Jr. | Jul 1970 | A |
3731683 | Zaffaroni | May 1973 | A |
3888247 | Stenvall | Jun 1975 | A |
3940362 | Overhults | Feb 1976 | A |
3983878 | Kawchitch | Oct 1976 | A |
3995641 | Kronenthal et al. | Dec 1976 | A |
4068664 | Sharp et al. | Jan 1978 | A |
4080348 | Korpman | Mar 1978 | A |
4126130 | Cowden et al. | Nov 1978 | A |
4140115 | Schonfeld | Feb 1979 | A |
4263906 | Finley | Apr 1981 | A |
4313865 | Teramoto et al. | Feb 1982 | A |
4340043 | Seymour | Jul 1982 | A |
4364876 | Kimura et al. | Dec 1982 | A |
4390519 | Sawyer | Jun 1983 | A |
4460369 | Seymour | Jul 1984 | A |
4560723 | Millet et al. | Dec 1985 | A |
4584355 | Blizzard et al. | Apr 1986 | A |
4585836 | Homan et al. | Apr 1986 | A |
4591622 | Blizzard et al. | May 1986 | A |
4612230 | Liland et al. | Sep 1986 | A |
4614183 | McCracken et al. | Sep 1986 | A |
4630603 | Greenway | Dec 1986 | A |
4655767 | Woodard et al. | Apr 1987 | A |
4671266 | Legnyel et al. | Jun 1987 | A |
4720513 | Kameyama et al. | Jan 1988 | A |
4728380 | Jones | Mar 1988 | A |
4733659 | Edenbaum et al. | Mar 1988 | A |
4767401 | Seiderman | Aug 1988 | A |
4793887 | Card et al. | Dec 1988 | A |
4793888 | Card et al. | Dec 1988 | A |
4795435 | Steer et al. | Jan 1989 | A |
4852571 | Gadsby et al. | Aug 1989 | A |
4867747 | Yarger | Sep 1989 | A |
4872450 | Austad | Oct 1989 | A |
4950282 | Beisang et al. | Aug 1990 | A |
4966605 | Thieler | Oct 1990 | A |
4999235 | Lunn et al. | Mar 1991 | A |
5035687 | Sandbank | Jul 1991 | A |
5059424 | Cartmell et al. | Oct 1991 | A |
5086763 | Hathman | Feb 1992 | A |
5088483 | Heinecke | Feb 1992 | A |
5106362 | Gilman | Apr 1992 | A |
5125907 | Philpott | Jun 1992 | A |
5164444 | Bernard | Nov 1992 | A |
5173302 | Holmblad et al. | Dec 1992 | A |
5232958 | Mallya et al. | Aug 1993 | A |
5254132 | Barley et al. | Oct 1993 | A |
5259835 | Clark et al. | Nov 1993 | A |
5266371 | Sugii et al. | Nov 1993 | A |
D347059 | Mota | May 1994 | S |
5308313 | Karami et al. | May 1994 | A |
5328687 | Leung et al. | Jul 1994 | A |
5336209 | Porzilli | Aug 1994 | A |
5415626 | Goodman et al. | May 1995 | A |
5429592 | Jensen | Jul 1995 | A |
5445597 | Clark et al. | Aug 1995 | A |
5449340 | Tollini | Sep 1995 | A |
D363126 | Dusek | Oct 1995 | S |
5456660 | Reich et al. | Oct 1995 | A |
5476440 | Edenbaum | Dec 1995 | A |
5486547 | Matsuda et al. | Jan 1996 | A |
D370258 | Newman | May 1996 | S |
D373750 | Gunderson | Sep 1996 | S |
5571079 | Bello et al. | Nov 1996 | A |
5575997 | Leung et al. | Nov 1996 | A |
5582834 | Leung et al. | Dec 1996 | A |
5599858 | Buchanan et al. | Feb 1997 | A |
5620702 | Podell et al. | Apr 1997 | A |
5623011 | Bernard | Apr 1997 | A |
5624669 | Leung et al. | Apr 1997 | A |
D382343 | Wandell et al. | Aug 1997 | S |
5653769 | Barley, Jr. et al. | Aug 1997 | A |
D383211 | Dunshee et al. | Sep 1997 | S |
5662599 | Reich et al. | Sep 1997 | A |
D387169 | Dunshee et al. | Dec 1997 | S |
D389244 | Dunshee et al. | Jan 1998 | S |
5705551 | Sasaki et al. | Jan 1998 | A |
D391639 | Dunshee et al. | Mar 1998 | S |
5749895 | Sawyer et al. | May 1998 | A |
5762955 | Smith | Jun 1998 | A |
5780048 | Lee | Jul 1998 | A |
5782788 | Widemire | Jul 1998 | A |
5823983 | Rosofsky et al. | Oct 1998 | A |
5823986 | Peterson | Oct 1998 | A |
D402371 | Haynes et al. | Dec 1998 | S |
D403425 | Hinds et al. | Dec 1998 | S |
D404139 | Young | Jan 1999 | S |
5861348 | Kase | Jan 1999 | A |
5876745 | Muraoka et al. | Mar 1999 | A |
5902443 | Kanakubo et al. | May 1999 | A |
5928611 | Leung | Jul 1999 | A |
5931800 | Rasmussen et al. | Aug 1999 | A |
5947917 | Carté et al. | Sep 1999 | A |
5951505 | Gilman et al. | Sep 1999 | A |
5998694 | Jensen et al. | Dec 1999 | A |
D424699 | Allen | May 2000 | S |
6093465 | Gilchrist et al. | Jul 2000 | A |
6125265 | Yamamoto et al. | Sep 2000 | A |
6140548 | Hansen et al. | Oct 2000 | A |
6143352 | Clark et al. | Nov 2000 | A |
6155265 | Hammerslag | Dec 2000 | A |
6183593 | Narang et al. | Feb 2001 | B1 |
D439973 | Choksi | Apr 2001 | S |
6217603 | Clark et al. | Apr 2001 | B1 |
6238692 | Smith | May 2001 | B1 |
6245960 | Eaton | Jun 2001 | B1 |
6284941 | Cox et al. | Sep 2001 | B1 |
6310166 | Hickey et al. | Oct 2001 | B1 |
6329564 | Lebner | Dec 2001 | B1 |
6352704 | Nicholson et al. | Mar 2002 | B1 |
D458687 | Dale et al. | Jun 2002 | S |
6410818 | Oyaski | Jun 2002 | B1 |
6439789 | Balance et al. | Aug 2002 | B1 |
D463564 | Siegwart et al. | Sep 2002 | S |
6455064 | Narang et al. | Sep 2002 | B1 |
6479725 | Brothers | Nov 2002 | B1 |
6482431 | Smith | Nov 2002 | B2 |
6512023 | Malofsky et al. | Jan 2003 | B1 |
D471984 | Dunshee et al. | Mar 2003 | S |
D472319 | Oltmann | Mar 2003 | S |
6559350 | Tetreault et al. | May 2003 | B1 |
6579469 | Nicholson et al. | Jun 2003 | B1 |
6582713 | Newell et al. | Jun 2003 | B2 |
D477076 | Wall | Jul 2003 | S |
6589269 | Zhu et al. | Jul 2003 | B2 |
6595940 | D'Alessio et al. | Jul 2003 | B1 |
6596917 | Oyaski | Jul 2003 | B2 |
6599318 | Gabbay | Jul 2003 | B1 |
6620846 | Jonn et al. | Sep 2003 | B1 |
D480879 | Boehm et al. | Oct 2003 | S |
6632450 | Gregory | Oct 2003 | B1 |
6635272 | Leaderman | Oct 2003 | B2 |
6652559 | Tetreault et al. | Nov 2003 | B1 |
6667051 | Gregory | Dec 2003 | B1 |
6712839 | Lönne | Mar 2004 | B1 |
6787682 | Gilman | Sep 2004 | B2 |
6837027 | Hickey | Jan 2005 | B2 |
6841716 | Tsutsumi | Jan 2005 | B1 |
6942683 | Dunshee | Sep 2005 | B2 |
D515701 | Horhota et al. | Feb 2006 | S |
D516728 | Wall | Mar 2006 | S |
D520639 | Dodd et al. | May 2006 | S |
7041124 | Purcell | May 2006 | B2 |
7044982 | Milbocker | May 2006 | B2 |
7066934 | Kirsch | Jun 2006 | B2 |
7122712 | Lutri et al. | Oct 2006 | B2 |
7144390 | Hannigan et al. | Dec 2006 | B1 |
7164054 | Mori et al. | Jan 2007 | B2 |
D548348 | Nash | Aug 2007 | S |
7252837 | Guo et al. | Aug 2007 | B2 |
D562461 | Nash et al. | Feb 2008 | S |
7371400 | Borenstein et al. | May 2008 | B2 |
D574962 | Atkins et al. | Aug 2008 | S |
D580553 | Nash | Nov 2008 | S |
D581467 | Winningham et al. | Nov 2008 | S |
7457667 | Skiba | Nov 2008 | B2 |
D582561 | Sachi | Dec 2008 | S |
D584415 | Sachi | Jan 2009 | S |
7576257 | LaGreca, Sr. | Aug 2009 | B2 |
D611156 | Dunshee | Mar 2010 | S |
7713463 | Reah et al. | May 2010 | B1 |
D618810 | Tanigawa et al. | Jun 2010 | S |
D621052 | Kase | Aug 2010 | S |
D621053 | Kase | Aug 2010 | S |
D624190 | Neri | Sep 2010 | S |
D632398 | Bray et al. | Feb 2011 | S |
D636881 | Clemens et al. | Apr 2011 | S |
7943811 | Da Silva Macedo, Jr. | May 2011 | B2 |
7981136 | Weiser | Jul 2011 | B2 |
7982087 | Greener et al. | Jul 2011 | B2 |
D646789 | Barth | Oct 2011 | S |
8343606 | Marchitto et al. | Jan 2013 | B2 |
8353966 | Day et al. | Jan 2013 | B2 |
D676490 | Bratter et al. | Feb 2013 | S |
8372051 | Scholz et al. | Feb 2013 | B2 |
D679098 | Ogawa | Apr 2013 | S |
D679402 | Conrad-Vlasak et al. | Apr 2013 | S |
D679403 | Heinecke et al. | Apr 2013 | S |
D679405 | Arbesman | Apr 2013 | S |
D679819 | Peron | Apr 2013 | S |
D679820 | Peron | Apr 2013 | S |
D685484 | Brambilla | Jul 2013 | S |
8528730 | Grossman | Sep 2013 | B2 |
D691730 | Smith et al. | Oct 2013 | S |
D692566 | Adoni | Oct 2013 | S |
D693010 | Mosa et al. | Nov 2013 | S |
D694892 | Chan et al. | Dec 2013 | S |
8603053 | Riesinger | Dec 2013 | B2 |
D697216 | Chan et al. | Jan 2014 | S |
8642831 | Larsen et al. | Feb 2014 | B2 |
8663171 | Tambourgi et al. | Mar 2014 | B2 |
D705429 | Cheney et al. | May 2014 | S |
D707829 | Chan et al. | Jun 2014 | S |
D708751 | Chan et al. | Jul 2014 | S |
8777986 | Straehnz et al. | Jul 2014 | B2 |
D712045 | Thornton | Aug 2014 | S |
D713534 | Manley, Jr. | Sep 2014 | S |
D713967 | Adoni | Sep 2014 | S |
D714575 | Mah | Oct 2014 | S |
8884094 | Lockwood et al. | Nov 2014 | B2 |
D718812 | Sukhbaatar | Dec 2014 | S |
9000251 | Murphy et al. | Apr 2015 | B2 |
RE45510 | Hisamitsu | May 2015 | E |
D728803 | Sinda et al. | May 2015 | S |
D745688 | Chan et al. | Dec 2015 | S |
D745689 | Chan et al. | Dec 2015 | S |
D746479 | Arefieg | Dec 2015 | S |
RE45864 | Peron | Jan 2016 | E |
D746996 | Karlsson et al. | Jan 2016 | S |
D750789 | Mackay et al. | Mar 2016 | S |
D757950 | Karlsson et al. | May 2016 | S |
9339417 | Ogawa | May 2016 | B2 |
9381284 | Cornet et al. | Jul 2016 | B2 |
9440010 | Locke | Sep 2016 | B2 |
9492171 | Patenaude | Nov 2016 | B2 |
9623142 | Jonn et al. | Apr 2017 | B2 |
D786350 | Nakai et al. | May 2017 | S |
D786351 | Nakai et al. | May 2017 | S |
D786352 | Nakai et al. | May 2017 | S |
D786353 | Nakai et al. | May 2017 | S |
D786972 | Nakai et al. | May 2017 | S |
9655622 | Jonn et al. | May 2017 | B2 |
D790071 | Ahsani | Jun 2017 | S |
D824525 | Lacy et al. | Jul 2018 | S |
D833526 | Nakai et al. | Nov 2018 | S |
10434211 | Jonn et al. | Oct 2019 | B2 |
10470935 | Quintero | Nov 2019 | B2 |
20010002432 | Bugge | May 2001 | A1 |
20010028943 | Mashiko et al. | Oct 2001 | A1 |
20010037077 | Wiemken | Nov 2001 | A1 |
20010051178 | Blatchford | Dec 2001 | A1 |
20020018689 | Badejo et al. | Feb 2002 | A1 |
20020019652 | DaSilva et al. | Feb 2002 | A1 |
20020037310 | Jonn et al. | Mar 2002 | A1 |
20020039867 | Curro et al. | Apr 2002 | A1 |
20020049503 | Milbocker | Apr 2002 | A1 |
20020185396 | Mainwaring et al. | Dec 2002 | A1 |
20020192107 | Hickey | Dec 2002 | A1 |
20020193721 | Vandruff | Dec 2002 | A1 |
20030031499 | Heard et al. | Feb 2003 | A1 |
20030050590 | Kirsch | Mar 2003 | A1 |
20030093024 | Falleiros et al. | May 2003 | A1 |
20030100955 | Greenawalt et al. | May 2003 | A1 |
20030109819 | Tsuruda et al. | Jun 2003 | A1 |
20030125654 | Malik | Jul 2003 | A1 |
20030175824 | Pishko et al. | Sep 2003 | A1 |
20030220596 | Dunshee | Nov 2003 | A1 |
20030225355 | Butler | Dec 2003 | A1 |
20040001879 | Guo et al. | Jan 2004 | A1 |
20040060867 | Kriksunov et al. | Apr 2004 | A1 |
20040106888 | Lutri et al. | Jun 2004 | A1 |
20040120849 | Stewart et al. | Jun 2004 | A1 |
20040142041 | MacDonald et al. | Jul 2004 | A1 |
20040162512 | Liedtke et al. | Aug 2004 | A1 |
20040220505 | Worthley | Nov 2004 | A1 |
20050015036 | Lutri et al. | Jan 2005 | A1 |
20050043820 | Browning | Feb 2005 | A1 |
20050085757 | Santanello | Apr 2005 | A1 |
20050147457 | Badejo et al. | Jul 2005 | A1 |
20050153090 | Marchitto et al. | Jul 2005 | A1 |
20050154340 | Schlussel | Jul 2005 | A1 |
20050182443 | Jonn et al. | Aug 2005 | A1 |
20050208100 | Weber et al. | Sep 2005 | A1 |
20050288706 | Widomski et al. | Dec 2005 | A1 |
20060009099 | Jonn et al. | Jan 2006 | A1 |
20060058721 | Lebner et al. | Mar 2006 | A1 |
20060141012 | Gingras | Jun 2006 | A1 |
20060173394 | Stroock et al. | Aug 2006 | A1 |
20060265005 | Beese | Nov 2006 | A1 |
20070106195 | Marcoux et al. | May 2007 | A1 |
20070218101 | Johnson et al. | Sep 2007 | A1 |
20070272211 | Kassner | Nov 2007 | A1 |
20070282238 | Madsen et al. | Dec 2007 | A1 |
20070299542 | Mathisen et al. | Dec 2007 | A1 |
20080051687 | Rogers | Feb 2008 | A1 |
20080154168 | Lutri | Feb 2008 | A1 |
20080086113 | Tenney et al. | Apr 2008 | A1 |
20080109034 | Mather et al. | May 2008 | A1 |
20080110961 | Voegele et al. | May 2008 | A1 |
20080167633 | Vannucci | Jul 2008 | A1 |
20080228219 | Weiser | Sep 2008 | A1 |
20080228220 | Weiser | Sep 2008 | A1 |
20080280037 | Sheridan et al. | Nov 2008 | A1 |
20080302487 | Goodman et al. | Dec 2008 | A1 |
20090074842 | Hsu | Mar 2009 | A1 |
20100106120 | Holm | Apr 2010 | A1 |
20100198161 | Propp | Aug 2010 | A1 |
20100262091 | Larsson | Oct 2010 | A1 |
20100298791 | Jones et al. | Nov 2010 | A1 |
20110047766 | McAulay et al. | Mar 2011 | A1 |
20110071415 | Karwoski et al. | Mar 2011 | A1 |
20110092874 | Baschnagel | Apr 2011 | A1 |
20110130699 | Madsen et al. | Jun 2011 | A1 |
20110208102 | Chawki | Aug 2011 | A1 |
20110253303 | Miyachi et al. | Oct 2011 | A1 |
20120052230 | Olsson et al. | Mar 2012 | A1 |
20120220912 | Shang | Aug 2012 | A1 |
20120238933 | Murphy et al. | Sep 2012 | A1 |
20120277645 | Kikuta et al. | Nov 2012 | A1 |
20130012988 | Blume et al. | Jan 2013 | A1 |
20130041337 | Aali et al. | Feb 2013 | A1 |
20130066365 | Belson et al. | Mar 2013 | A1 |
20130084323 | Riebman et al. | Apr 2013 | A1 |
20130138068 | Hu et al. | May 2013 | A1 |
20130143326 | Tai et al. | Jun 2013 | A1 |
20130144399 | Tai et al. | Jun 2013 | A1 |
20130204077 | Nagale et al. | Aug 2013 | A1 |
20130218125 | Stopek et al. | Aug 2013 | A1 |
20130245784 | Tan et al. | Sep 2013 | A1 |
20130274717 | Dunn | Oct 2013 | A1 |
20130282049 | Peterson et al. | Oct 2013 | A1 |
20130317405 | Ha et al. | Nov 2013 | A1 |
20140024989 | Ueda | Jan 2014 | A1 |
20140107561 | Dorian et al. | Apr 2014 | A1 |
20140121649 | Calco | May 2014 | A1 |
20140155916 | Hodgkinson et al. | Jun 2014 | A1 |
20140171888 | Croizat et al. | Jun 2014 | A1 |
20140257348 | Priewe et al. | Sep 2014 | A1 |
20140257517 | Deichmann et al. | Sep 2014 | A1 |
20150057491 | Goddard et al. | Feb 2015 | A1 |
20150209186 | Abbott et al. | Jul 2015 | A1 |
20150257938 | Pensier | Sep 2015 | A1 |
20150297413 | Blanco | Oct 2015 | A1 |
20150314114 | La Rosa | Nov 2015 | A1 |
20150351767 | Zoll et al. | Dec 2015 | A1 |
20160030248 | Potters | Feb 2016 | A1 |
20160089145 | Quintero et al. | Mar 2016 | A1 |
20160199230 | Doshi | Jul 2016 | A1 |
20160296673 | Sambusseti | Oct 2016 | A1 |
20170035422 | Belson | Feb 2017 | A1 |
20170056568 | Shelton, IV et al. | Mar 2017 | A1 |
20170056569 | Vendely et al. | Mar 2017 | A1 |
20170189159 | Bartee et al. | Jul 2017 | A1 |
20170273837 | Brueckner | Sep 2017 | A1 |
20170367806 | Gingras et al. | Dec 2017 | A1 |
20180085103 | Quintero et al. | Mar 2018 | A1 |
20180085259 | Quintero | Mar 2018 | A1 |
20180085260 | Quintero | Mar 2018 | A1 |
20190381207 | Jonn et al. | Dec 2019 | A1 |
Number | Date | Country |
---|---|---|
2005-215776 | Sep 2005 | AU |
2262408 | Aug 2000 | CA |
1697639 | Nov 2005 | CN |
201441532 | Apr 2010 | CN |
101965169 | Feb 2011 | CN |
102755216 | Oct 2012 | CN |
102781433 | Nov 2012 | CN |
203234898 | Oct 2013 | CN |
204766892 | Nov 2015 | CN |
0532275 | Mar 1993 | EP |
0730874 | Sep 1996 | EP |
0746293 | Dec 1996 | EP |
1161212 | Aug 2000 | EP |
2359782 | Aug 2011 | EP |
2377498 | Oct 2011 | EP |
2731563 | May 2014 | EP |
2531155 | Oct 2014 | EP |
2805698 | Nov 2014 | EP |
3574875 | Dec 2019 | EP |
2078763 | Jan 1982 | GB |
59-500046 | Jan 1984 | JP |
61-203020 | Dec 1986 | JP |
62-87624 | Jun 1987 | JP |
01-265967 | Oct 1988 | JP |
2-140948 | Nov 1990 | JP |
3-56429 | May 1991 | JP |
06-509966 | Nov 1994 | JP |
7-016258 | Jan 1995 | JP |
2001-265967 | Sep 2001 | JP |
1130927 | Nov 2001 | JP |
2002-512980 | May 2002 | JP |
2002-521139 | Jul 2002 | JP |
2002-537068 | Nov 2002 | JP |
2003-052741 | Feb 2003 | JP |
2003-153949 | May 2003 | JP |
58-124123 | Jan 2004 | JP |
2004-24905 | Jan 2004 | JP |
2006-061263 | Mar 2006 | JP |
2006-509966 | Mar 2006 | JP |
2007-522882 | Aug 2007 | JP |
3147394 | Dec 2008 | JP |
2009-022730 | Feb 2009 | JP |
1359502 | May 2009 | JP |
2011-004850 | Jan 2011 | JP |
1571238 | Mar 2017 | JP |
1629290 | Apr 2019 | JP |
241113 | Oct 2006 | MX |
WO 1983002586 | Aug 1983 | WO |
WO 1993004650 | Mar 1993 | WO |
WO 1995004511 | Feb 1995 | WO |
WO 1996040797 | Dec 1996 | WO |
WO 1998026719 | Jun 1998 | WO |
WO 2000006213 | Feb 2000 | WO |
WO 2000049983 | Aug 2000 | WO |
WO 2003008002 | Jan 2003 | WO |
WO 2004049987 | Jun 2004 | WO |
WO 2005007020 | Jan 2005 | WO |
WO 2005051259 | Jun 2005 | WO |
WO 2005079674 | Sep 2005 | WO |
WO 2006017109 | Feb 2006 | WO |
WO 2008082444 | Jul 2008 | WO |
WO 2009067062 | May 2009 | WO |
WO 2010134873 | Nov 2010 | WO |
2011152368 | Dec 2011 | WO |
WO 2013009725 | Jan 2013 | WO |
WO 2014083570 | Jun 2014 | WO |
WO 2014195710 | Dec 2014 | WO |
WO 2015135351 | Sep 2015 | WO |
Entry |
---|
U.S. Appl. No. 12/207,984, filed Sep. 10, 2008, US-2009-0076542-A1, U.S. Pat. No. 9,655,622, May 23, 2017, Grant, Jonn, et al. |
U.S. Appl. No. 15/490,176, filed Apr. 18, 2017, US-2017-0216482, U.S. Pat. No. 10,434,211, Oct. 8, 2019, Grant, Jonn, et al. |
U.S. Appl. No. 15/964,538, filed Apr. 27, 2018, US-2018-0243467, U.S. Pat. No. 10,398,802, Sep. 3, 2019, Grant, Jonn, et al. |
U.S. Appl. No. 16/556,443, filed Aug. 30, 2019, US-2019-0381207, Publication, Jonn, et al. |
U.S. Appl. No. 10/779,721, filed Feb. 18, 2004, US-2005-0182443-A1, Abandoned. |
U.S. Appl. No. 16/556,471, filed Aug. 30, 2019, US-2019-0381206, Publication, Jonn, et al. |
U.S. Appl. No. 12/163,021, filed Jun. 27, 2008, US-2008-0255610-A1, U.S. Pat. No. 9,623,142, Apr. 18, 2017, Grant, Jonn, et al. |
U.S. Appl. No. 15/452,126, filed Mar. 7, 2017, US-2017-0173208, U.S. Pat. No. 10,398,800, Sep. 3, 2019, Grant, Jonn, et al. |
U.S. Appl. No. 10/887,884, filed Jul. 12, 2004, US-2006-0009099-AI, Abandoned |
U.S. Appl. No. 14/864,033, filed Sep. 24, 2015, US2016-0089145, Publication, Quintero, et al. |
U.S. Appl. No. 16/387,634, filed Apr. 18, 2019, US-2019-0240074, Publication, Quintero, et al. |
U.S. Appl. No. 29/635,782, filed Feb. 2, 2018, Filing, Quintero, et al. |
U.S. Appl. No. 29/503,320, filed Sep. 25, 2014, U.S. Pat. No. D824,525, Jul. 31, 2018, Grant, Quintero, et al. |
U.S. Appl. No. 29/648,487, filed May 22, 2018, U.S. Pat. No. D854,171, Jul. 16, 2019, Grant, Quintero, et al. |
U.S. Appl. No. 29/690,950, filed May 13, 2019, Filing, Quintero, et al. |
U.S. Appl. No. 15/675,159, filed Aug. 11, 2017, US-2018-0085260, U.S. Pat. No. 10,687,986, Jun. 23, 2020, Grant, Quintero, et al. |
U.S. Appl. No. 16/907,930, filed Jun. 22, 2020, US-2020-0315858, Publication, Quintero, et al. |
U.S. Appl. No. 29/613,662, filed Aug. 11, 2017, U.S. Pat. No. D848,624, May 14, 2019, Grant, Quintero, et al. |
U.S. Appl. No. 29/683,074, filed Mar. 11, 2019, U.S. Pat. No. D907,217, Jan. 5, 2021, Grant, Quintero, et al. |
U.S. Appl. No. 29/761,282, filed Dec. 8, 2020, Filing, Quintero, et al. |
U.S. Appl. No. 15/280,303, filed Sep. 29, 2016, US-2018-0085259, U.S. Pat. No. 10,470,934, Nov. 12, 2019, Grant, Quintero, et al. |
U.S. Appl. No. 16/598,249, filed Oct. 10, 2019, US-2020-0038253, Publication, Quintero, et al. |
U.S. Appl. No. 15/467,537, filed Mar. 23, 2017, US-2018-0271712, U.S. Pat. No. 10,470,935, Nov. 12, 2019, Grant, Quintero, et al. |
U.S. Appl. No. 17/143,883, filed Jan. 7, 2021, Filing, Quintero, et al. |
U.S. Appl. No. 15/496,389, filed Apr. 25, 2017, US-2018-0303967, Publication, Quintero, et al. |
U.S. Appl. No. 16/050,205, filed Jul. 31, 2018, US-2020-0038006, Publication, Quintero, et al. |
JP 7040744, 1995, English claims. |
JP 3059327, 1991, English claims. |
Japanese Office Action dated Feb. 19, 2019 for Design Appln. No. 2018-017274. |
Japanese Office Action dated Feb. 26, 2019 for Patent Appln. No. 515463. |
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 4 pages. |
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2011) 8 pages. |
3M™ Steri-Strip Adhesive Closures Product Catalog Brochure, (2012) 12 pages. |
Allen, L.V. Jr et al Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, 8th edition 2005 Lippincott Williams & Wilkins, Chapter 4, Dosage Form Design: Pharmaceutical and Formulation Considerations p. 131. |
Ashley et al.: Further studies involving wound closure with a rapidly polymerizing adhesive; Plastic and Reconstructive Surgery; Apr. 1963; vol. 31; pp. 333-343. |
Ashley et al.: Nonsutured closure of skin lacerations and nonsutured grafting of skin with a rapidly polymerizing adhesive; Qtrly Bull. Northwestern University (Evanston, III.) Medical School; 1962; vol. 36; pp. 189-194. |
Brombeg et al.: Nonsuture fixation of split-thickness skin grafts; Surgery, Jun. 1964; vol. 55; pp. 846-853. |
Cramer: Rapid Skin Grafting in Small Animals; Plastic and Reconstructive Surgery and the Transplantation Bull; Oct. 1962, vol. 30; pp. 149-150. |
Cramer et al.: Autograft rejection induced by homografting. A phenomenon intermediate between homograft rejection and autoimmunity; Plastic and Reconstructive Surgery; Jun. 1965; vol. 35; pp. 572-587. |
Demaria, E. ‘New skin closure system facilitates wound healing after cardiovascular implantable electronic device surgery’ World Journal of Clinical Cases (2015) 3(8) pp. 675-677. |
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2014), 7 pages. |
Dermabond Prineo Skin Closure Systems (22 cm) Brochure (2015), 2 pages. |
Healthcare Packaging. Advanced Wound Care Products and packaging Needs. Jun. 5, 2017 (earliest online date), [site visited May 8, 2018]. Available from the Internet, URL:https://www.healthcarepackaging.com/article/applications/healthcare/advanced-wound-care-products-and-packaging-needs> (Year: 2017). |
Inou: Studies on the Surgical Use of Plastic Adhesive; Am. Journal of Proctology; 1962; vol. 13; pp. 219-226. |
Jesse et al.: Fixation of split-thickness skin grafts with adhesive; Plastic and Reconstructive Surgery; Mar. 1964; vol. 33; pp. 272-277. |
Kaplan: A technique of nonsuture wound closure with a plastic tissue adhesive; Plastic and Reconstructive Surgery; Feb. 1966; vol. 37(2); pp. 139-142. |
Keddie et al.: Intrafollicular tinea versicolor demonstrated on monomer plastic strips; Journal of Investigative Dermatology; Sep. 1963; vol. 41; pp. 103-106. |
Lazar, H.L. et al. ‘Novel Adhesive Skin Closures Improve Wound Healing Following Saphenous Vein Harvesting’ J. Card Surg (2008) 23 pp. 152-155. |
Leukosan SkinLink Application Guide (2006) 1 page. |
Leukosan Skinlink. BSN Medical (2017) 1 page http://www.bsnmedical.com/products/wound%E2%80%90care%E2%80%90vascular/category%E2%80%90product%E2%80%90search/acute%E2%80%90wound%E2%80%90care/wound%E2%80%90closure/leukosanr%E2%80%90skinlink.html. |
Pam Marketing Nut. Yikes! The Social Medica Quick Fix Band-Aids are Falling Off! Jul. 2012 [earliest online date], [site visited May 8, 2018]. Available from Internet, ,URL:http://www.pammarketingnut.com/2012/07/yikes-the-social-media-quick-fix-band-aids-are-falling-off/> (Year: 2012). |
Parrish et al.: Synthetic resin adhesive for placement of skin grafts; American Surgeon; Nov. 1964; vol. 30; pp. 753-755. |
Raekallio et al.: Acute reaction to arterial adhesive in healing skin wounds; Journal of Surgical Research; Mar. 1964; vol. 4; pp. 124-127. |
Stone: Nonsuture closure of cutaneous lacerations, skin grafting and bowel anastomosis; American Surgeon; Mar. 1964; vol. 30; pp. 177-181. |
TissuGlu Surgical Adhesive Patient Information Brochure. Cohera Medical, Inc. (2014) 6 pages. |
TissuGlu FDA Summary of Safety and Effectiveness Data. Feb. 3, 2014 40 pages. |
Topaz, M et al ‘The TopClosure 3S System, for skin stretching and a secure wound closure’ Eur J Plast Surg (2012) 35 pp. 533-543. |
TopClosure 3S System—Skin Stretching and Secure Wound Closure System Product Information Sheet (2010) 15 pages. |
Wang et al ‘Biodegradable microfluidic scaffolds for tissue engineering from amino alcohol-based poly(ester amide) elastomers’ Organogenesis (2010) 6:4, pp. 212-216. |
Wolfe et al.: The application of hydrostatic pressure to the burn injury, an experimental study: Journal of Trauma: Injury Infections & critical Care; May 1962; vol. 2; pp. 262-272. |
ZipLine medical Zip Surgical Skin Closure Brochure (2013) 4 pages. |
Corrected International Search Report International Application No. PCT/US2005/004948 dated Jun. 22, 2005. |
Extended European Search Report re: 14166813.7 dated Jul. 7, 2014. |
International Preliminary Report on Patentability for International Application No. PCT/US2005/024042 dated Jan. 16, 2007. |
International Search Report for International Application No. PCT/US2005/024042 dated May 12, 2006. |
International Search Report for International Application No. PCT/US2005/004948 dated Jun. 9, 2009. |
International Search Report re: PCT/US2015/051919 dated Apr. 14, 2016. |
International Search Report re: PCT/US2017/052394 dated Nov. 21, 2017. |
International Search Report re: PCT/US2017/052383 dated Dec. 6, 2017. |
International Search Report re PCT/US2018/022842 dated Jun. 20, 2018. |
International Search Report re PCT/US2018/022834 dated Jun. 22, 2018. |
International Search Report re PCT/US2018/027790 dated Jun. 26, 2018. |
Supplementary European Search Report for Application No. EP05769387 dated Jul. 9, 2009. |
Supplementary European Search Report for Application No. EP05723162 dated Nov. 5, 2009. |
Supplementary European Search Report for Application No. EP14166813 dated Jun. 30, 2014. |
Written Opinion re: PCT/US2015/051919 dated Apr. 14, 2016. |
Written Opinion re: PCT/US2017/052394 dated Nov. 21, 2017. |
Written Opinion re: PCT/US2017/052383 dated Dec. 6, 2017. |
Written Opinion re: PCT/US2018/022842 dated Jun. 20, 2018. |
Written Opinion re: PCT/US2018/027790 dated Jun. 26, 2018. |
Written Opinion re PCT/US2018/022834 dated Jun. 22, 2018. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Aug. 11, 2006. |
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Mar. 28, 2007. |
Communication received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Apr. 16, 2007. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008. |
Communication received from the USPTO for co-pending U.S. Appl. No. 10/887,884 dated Dec. 12, 2008. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated May 11, 2011. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Feb. 2, 2012. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012. |
Communication received from the USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jun. 28, 2012. |
Communication received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jun. 22, 2012. |
In re the U.S. Appl. No. 12/163,021 the Non-Final rejection dated Aug. 14, 2013. |
In re the U.S. Appl. No. 12/163,021 the Final rejection dated Jan. 3, 2014. |
In re the U.S. Appl. No. 12/207,984 the Non-Final rejection dated Aug. 22, 2013. |
In re the U.S. Appl. No. 12/207,984 the Final rejection dated Dec. 4, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Apr. 25, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Aug. 21, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 12, 2006. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jan. 9, 2007. |
Office Communication received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Jan. 22, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Feb. 1, 2007. |
Office Action received from the USPTO for co-pending U.S. Appl. No. 12/163,021. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated Jul. 27, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Oct. 16, 2007. |
Office Action received from USPTO for co-pending U.S. Appl. No. 10/887,884 dated Mar. 6, 2008. |
Office action received from USPTO for co-pending U.S. Appl. No. 10/779,721 dated May 19, 2008. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 1, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 1, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Dec. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 9, 2010. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 13, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jul. 18, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 1, 2011. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 10, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Jan. 17, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Apr. 26, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated May 1, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Sep. 17, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Sep. 25, 2012. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Aug. 14, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Aug. 22, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/207,984 dated Dec. 4, 2013. |
Office action received from USPTO for co-pending U.S. Appl. No. 12/163,021 dated Jan. 3, 2014. |
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Oct. 25, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/964,538 dated Dec. 27, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/490,176 dated Feb. 4, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/452,126 dated Nov. 16, 2018. |
Office action received from USPTO for U.S. Appl. No. 14/864,033 dated Nov. 26, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/467,239 dated Feb. 28, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Sep. 11, 2018. |
Office action received from USPTO for U.S. Appl. No. 15/278,376 dated Feb. 21, 2019. |
Office action received from USPTO for U.S. Appl. No. 15/675,159 dated May 14, 2019. |
U.S. Appl. No. 09/430,177, filed Oct. 29, 1999. |
U.S. Appl. No. 09/430,289, filed Oct. 29, 1999. |
U.S. Appl. No. 09/430,180, filed Oct. 29, 1999. |
U.S. Appl. No. 09/385,030, filed Aug. 30, 1999. |
U.S. Appl. No. 09/176,889, filed Oct. 22, 1998. |
U.S. Appl. No. 09/919,877, filed Aug. 2, 2001. |
U.S. Appl. No. 10/779,721, filed Feb. 18, 2004. |
N/A, “Scar nose & Rinoplasty Surgery—New Gel+Demo:Nose Silicone Gel Sheet (beige)www.newgelplus.com”, www.youtube.com, 2012, pp. 1-3, Page Number. |
N/A, “Silagen Silicone Sheeting Strips Review|the skin spot”, www.youtube.com, 2017, pp. 1-3, Page Number. |
Number | Date | Country | |
---|---|---|---|
20200038253 A1 | Feb 2020 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15467537 | Mar 2017 | US |
Child | 16598249 | US |